tumor → CapableOf → acquired resistance
Typicality: 0.318
Saliency: 0.159
Facets 2
to gefitinib 3 transitive-object
to platinum-based treatments 2 transitive-object
Open triples 2
tumor → acquired → resistance 5
tumor → develop → acquired resistance 3
Sentiment analysis
negative neutral positive
0.408 0.516 0.076
Other statistics
Raw frequency 8
Normalized frequency 0.159
Modifier score 0.500
Perplexity 172.131